[No abstract available]5SUPPL. 13448Engelhardt, E., Brucki, S.M., Cavalcanti, J.L., Forlenza, O.V., Laks, J., Vale, F.A., Treatment of Alzheimer's disease: Recommendations and suggestions of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology (2005) Arq Neuropsiquiatr, 63, pp. 1104-1112. , Departamento de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de NeurologiaGronseth, G., French, J., Practice parameters and technology assessments: What they are, what they are not, and why you should care (2008) Neurology, 71, pp. 1639-643French, J., Gronseth, G., Lost in a jungle of evidence: We need a compass (2008) Neurology, 71, pp. 1634-1638McKhann, G.M., Knopman, D.S., Chertkow, H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) Alzheimers Dement, 7, pp. 263-269McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34, pp. 939-944Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup, , Alzheimers Dement Apr 20Sperling, R.A., Aisen, P.S., Beckett, L.A., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) Alzheimers Dement, 7, pp. 280-292Nordberg, A., Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications (2001) Biol Psychiatry, 49, pp. 200-210Peters, B.H., Levin, H.S., Effects of physostigmine and lecitin on memory in Alzheimer's disease (1979) Ann Neurol, 6, pp. 219-221Summers, W.K., Majovski, L.V., Marsh, G.M., Tachiki, K., Kling, A., Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type (1986) N Engl J Med, 315, pp. 1241-1245Corey-Bloom, J., Anand, R., Veach, J., A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetyl-chonesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease (1998) Int. J Geriatr Psychopharmacol, 1, pp. 55-65Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R., Friedhoff, L.T., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group (1998) Neurology, 50, pp. 136-145Raskind, M.A., Peskind, E.R., Wessel, T., Yuan, W., Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group (2000) Neurology, 54, pp. 2261-2268Hansen, R.A., Gartlehner, G., Webb, A.P., Morgan, L.C., Moore, C.G., Jonas, D.E., Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis (2008) Clin Interv Aging, 3, pp. 211-225Lockhart, I.A., Mitchell, S.A., Kelly, S., Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: Systematic review of the "real-world" evidence (2009) Dement Geriatr Cogn Disord, 28, pp. 389-403Winblad, B., Gauthier, S., Scinto, L., Safety and efficacy of galantamine in subjects with mild cognitive impairment (2008) Neurology, 70, pp. 2024-2035. , GAL-INT-11/18 Study GroupBurns, A., Bernabei, R., Bullock, R., Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the CERAD study): A randomized, placebo-controlled, double-blind trial (2009) Lancet Neurol, 8, pp. 39-47Farlow, M.R., Grossberg, G.T., Meng, X., Olin, J., Somogyi, M., (2010) Rivastigmine transdermal patch and capsule in Alzheimer's disease: Influence of disease stage on response to therapy, , Int J Geriatr Psychiatry Dec 23. [Epub ahead of print]Winblad, B., Black, S.E., Homma, A., Donepezil treatment in severe Alzheimer's disease: A pooled analysis of three clinical trials (2009) Curr Med Res Opin, 25, pp. 2577-2587Jarvis, B., Figgitt, D.P., Memantine (2003) Drugs Aging, 20 (6), pp. 465-76. , discussion 477-8Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H.J., Memantine in moderate-to-severe Alzheimer's disease (2003) N Engl J Med, 348, pp. 1333-1341. , Memantine Study GroupTariot, P.N., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S., Gergel, I., Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial (2004) JAMA, 291, pp. 317-324. , Memantine Study GroupWinblad, B., Jones, R.W., Wirth, Y., Stoffler, A., Mobius, H.J., Memantine in moderate to severe Alzheimer's disease: A meta-analysis of randomised clinical trials (2007) Dement Geriatr Cogn Disord, 24, pp. 20-27Atri, A., Shaughnessy, L.W., Locascio, J.J., Growdon, J.H., Long-term course and effectiveness of combination therapy in Alzheimer disease (2008) Alzheimer Dis Assoc Disord, 22, pp. 209-221Shua-Haim, J., Smith, J., Picard, F., Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: An open-label, crossover, single-centre study (2008) Clin Drug Investig, 28, pp. 361-374Grossberg, G.T., Edwards, K.R., Zhao, Q., Rationale for combination therapy with galantamine and memantine in Alzheimer's disease (2006) J Clin Pharmacol, 46 (7 SUPPL. 1), pp. S17-S26Zhu, C.W., Livote, E.E., Kahle-Wrobleski, K., (2010) Longitudinal medication usage in Alzheimer disease patients, , Alzheimer Dis Assoc Disord Jul 9McShane, R., Areosa, S.A.N.M., Memantine for dementia (2011) Cochrane Database of Systematic Reviews, p. 003154Peskind, E.R., Potkin, S.G., Pomara, N., Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial (2006) Am J Geriatr Psychiatry, 14, pp. 704-715Porsteinsson, A.P., Grossberg, G.T., Mintzer, J., Olin, J.T., Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial (2008) Curr Alzheimer Res, 5, pp. 83-89. , Memantine MEM-MD-12 Study GroupDoody, R.S., Tariot, P.N., Pfeiffer, E., Olin, J.T., Graham, S.M., Meta-analysis of six-month memantine trials in Alzheimer's disease (2007) Alzheimers Dement, 3, pp. 7-17Schneider, L.S., Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease. " Wuthering forest plots: Distinguishing the forest from the plots (2007) Alzheimers Dement, 3, pp. 18-20Knopman, D.S., Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease. " Memantine has negligible benefits in mild to moderate Alzheimer's disease (2007) Alzheimers Dement, 3, pp. 21-22Schneider, L.S., Insel, P.S., Weiner, M.W., Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative (2011) Arch Neurol, 68, pp. 58-66. , Alzheimer's Disease Neuroimaging InitiativeLuo, Y., Smith, J.V., Paramasivam, V., Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761 (2002) Proc Natl Acad Sci U S A, 99, pp. 12197-202Smith, J.V., Luo, Y., Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761 (2003) J Alzheimers Dis, 5, pp. 287-300Mix, J.A., Crews Jr., W.D., A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: Neuropsychological findings (2002) Hum Psychopharmacol, 17, pp. 267-277Birks, J., Evans, G., Ginkgo biloba for cognitive impairment and dementia (2009) Cochrane Database Syst Rev, (1), pp. CD003120Dodge, H.H., Zitzelberger, T., Oken, B.S., Howieson, D., Kaye, J., A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline (2008) Neurology, 70, pp. 1809-1817de Kosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Ginkgo biloba for prevention of dementia: A randomized controlled trial (2008) JAMA, 300, pp. 2253-2262. , Ginkgo Evaluation of Memory (GEM) Study InvestigatorsSnitz, B.E., O'Meara, E.S., Carlson, M.C., Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial (2009) JAMA, 302, pp. 2663-2670. , Ginkgo Evaluation of Memory (GEM) Study InvestigatorsBerman, K., Brodaty, H., Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders (2004) CNS Drugs, 18, pp. 807-825Morris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Wilson, R.S., Vitamin E and cognitive decline in older persons (2002) Arch Neurol, 59, pp. 1125-1132Sano, M., Ernesto, C., Thomas, R.G., A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease Cooperative Study (1997) N Engl J Med, 336, pp. 1216-1222Petersen, R.C., Thomas, R.G., Grundman, M., Vitamin E and donepezil for the treatment of mild cognitive impairment (2005) N Engl J Med, 352, pp. 2379-2388. , Alzheimer's Disease Cooperative Study GroupIsaac, M.G., Quinn, R., Tabet, N., Vitamin E for Alzheimer disease and mild cognitive impairment (2008) Cochrane Database Syst Rev, (3), pp. CD002854Miller III, E.R., Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E., Meta-analysis: High dosage vitamin E supplemention may increase all-cause mortality (2005) Ann Intern Med, 142, pp. 37-46Dysken, M.W., Kirk, L.N., Kuskowski, M., Changes in vitamin E prescribing for Alzheimer patients (2009) Am J Geriatr Psychiatry, 17, pp. 621-624Birks, J., Flicker, L., Selegiline for Alzheimer's disease (2003) Cochrane Database Syst Rev, (1). , CD000442Irving, G.F., Freund-Levi, Y., Eriksdotter-Jönhagen, M., Omega-3 Fatty Acid Supplementation Effects on Weight and Appetite in Patients with Alzheimer's Disease: The omega-3 Alzheimer's Disease Study (2009) J Am Geriatr Soc, 57, pp. 11-17Lim, W.S., Gammack, J.K., van Niekerk, J., Dangour, A.D., Omega 3 fatty acid for the prevention of dementia (2006) Cochrane Database Syst Rev, (1). , CD005379Freund-Levi, Y., Basun, H., Cederholm, T., Omega-3 supplementation in mild to moderate Alzheimer's disease: Effects on neuropsychiatric symptoms (2008) Int J Geriatr Psychiatry, 23, pp. 161-169Dangour, A.D., Whitehouse, P.J., Rafferty, K., B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: A systematic review (2010) J Alzheimers Dis, 22, pp. 205-224Aisen, P.S., Schneider, L.S., Sano, M., High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial (2008) JAMA, 300, pp. 1774-1783. , Alzheimer Disease Cooperative StudyFord, A.H., Flicker, L., Alfonso, H., Vitamins B(12), B(6), and folic acid for cognition in older men (2010) Neurology, 75, pp. 1540-1547Malouf, R., Grimley Evans, J., Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people (2008) Cochrane Database Syst Rev, (4). , CD004514Henderson, V.W., Paganini-Hill, A., Miller, B.L., Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial (2000) Neurology, 54, pp. 295-301Mulnard, R.A., Cotman, C.W., Kawas, C., Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's disease Cooperative Study (2000) JAMA, 283, pp. 1007-1015Shumaker, S.A., Legault, C., Rapp, S.R., Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial (2003) JAMA, 289, pp. 2651-2662. , WHIMS InvestigatorsShumaker, S.A., Legault, C., Kuller, L., Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study (2004) JAMA, 291, pp. 2947-2958. , Women's Health Initiative Memory StudyHenderson, V.W., Estrogen-containing hormone therapy and Alzheimer's disease risk: Understanding discrepant inferences from observational and experimental research (2006) Neuroscience, 138, pp. 1031-1039Sano, M., Jacobs, D., Andrews, H., A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: Design and baseline characteristics (2008) Clin Trials, 5, pp. 523-533Veld, B.A., Ruitenberg, A., Hofman, A., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease (2001) N Engl J Med, 345, pp. 1515-1521Aisen, P.S., Schafer, K.A., Grundman, M., Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial (2003) JAMA, 289, pp. 2819-2826. , Alzheimer's Disease Cooperative StudyTabet, N., Feldmand, H., Ibuprofen for Alzheimer's disease (2003) Cochrane Database Syst Rev, (2). , CD004031de Jong, D., Jansen, R., Hoefnagels, W., No effect of one-year treatment with indomethacin on Alzheimer's disease progression: A randomized controlled trial (2008) PLoS One, 3, pp. e1475Martin, B.K., Szekely, C., Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib (2008) Arch Neurol, 65, pp. 896-905. , ADAPT Research GroupLi, G., Higdon, R., Kukull, W.A., Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study (2004) Neurology, 63, pp. 1624-1628Zamrini, E., McGwin, G., Roseman, J.M., Association between statin use and Alzheimer's disease (2004) Neuroepidemiology, 23, pp. 94-98Zhou, B., Teramukai, S., Fukushima, M., Prevention and treatment of dementia or Alzheimer's disease by statins: A meta-analysis (2007) Dement Geriatr Cogn Disord, 23, pp. 194-201Feldman, H.H., Doody, R.S., Kivipelto, M., Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe (2010) Neurology, 74, pp. 956-964. , LEADe InvestigatorsMcGuinness, B., O'Hare, J., Craig, D., Bullock, R., Malouf, R., Passmore, P., Statins for the treatment of dementia (2010) Cochrane Database Syst Rev, (8). , CD007514van Paasschen, J., Clare, L., Woods, R.T., Linden, D.E., Can we change brain functioning with cognition-focused interventions in Alzheimer's disease? The role of functional neuroimaging (2009) Restor Neurol Neurosci, 27, pp. 473-491Chapman, S.B., Weiner, M.F., Rackley, A., Hynan, L.S., Zientz, J., Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil (2004) J Speech Lang Hear Res, 47, pp. 1149-1163Requena, C., Maestú, F., Campo, P., Fernández, A., Ortiz, T., Effects of cholinergic drugs and cognitive training on dementia: 2-year follow-up (2006) Dement Geriatr Cogn Disord, 22, pp. 339-345Olazarán, J., Reisberg, B., Clare, L., Nonpharmacological therapies in Alzheimer's disease: A systematic review of efficacy (2010) Dement Geriatr Cogn Disord, 30, pp. 161-178Cotelli, M., Calabria, M., Zanetti, O., Cognitive rehabilitation in Alzheimer's disease (2006) Aging Clin Exp Res, 18, pp. 141-143Onder, G., Zanetti, O., Giacobini, E., Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: Randomised controlled trial (2005) Br J Psychiatry, 187, pp. 450-455Yamaguchi, H., Maki, Y., Yamagami, T., Overview of non-pharmacological intervention for dementia and principles of brain-activating rehabilitation (2010) Psychogeriatrics, 10, pp. 206-213Haslam, C., Gilroy, D., Black, S., Beesley, T., How successful is errorless learning in supporting memory for high and low-level knowledge in dementia? (2006) Neuropsychol Rehabil, 16, pp. 505-536Rothi, L.J., Fuller, R., Leon, S.A., Errorless practice as a possible adjuvant to donepezil in Alzheimer's disease (2009) J Int Neuropsychol Soc, 15, pp. 311-322Yu, F., Rose, K.M., Burgener, S.C., Cognitive training for early-stage Alzheimer's disease and dementia (2009) J Gerontol Nurs, 35, pp. 23-29Hogan, D.B., Bailey, P., Black, S., Diagnosis and treatment of dementia: Nonpharmacologic and pharmacologic therapy for mild to moderate dementia (2008) CMAJ, 179, pp. 1019-1026Heyn, P., Abreu, B.C., Ottenbacher, K.J., The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis (2004) Arch Phys Med Rehabil, 85, pp. 1694-1704Lautenschlager, N.T., Cox, K., Kurz, A.F., Physical activity and mild cognitive impairment and Alzheimer's disease (2010) Curr Neurol Neurosci Rep, 10, pp. 352-358Forbes, D., Forbes, S., Morgan, D.G., Markle-Reid, M., Wood, J., Culum, I., Physical activity programs for persons with dementia (2008) Cochrane Database Syst Rev, (3). , CD006489Rolland, Y., Pillard, F., Klapouszczak, A., Exercise program for nursing home residents with Alzheimer's disease: A 1-year randomized, controlled trial (2007) J Am Geriatr Soc, 55, pp. 158-165Apostolova, L.G., Cummings, J.L., Neuropsychiatric manifestations in mild cognitive impairment: A systematic review of the literature (2008) Dement Geriatr Cogn Disord, 25, pp. 115-126Fillit, H.M., The pharmacoeconomics of Alzheimer's disease (2000) Am J Manag Care, 6 (22 SUPPL.), pp. S1139-S1144Buhr, G.T., White, H.K., Difficult behaviors in long-term care patients with dementia (2006) J Am Med Dir Assoc, 7, pp. 180-192(2007) Interpretive guidelines for long-term care facilities, , Department of Health and Human Services, State Operations Manual, Appendix PP-Guidance to Surveyors for Long Term Care Facilities, Accessed August 21 cms.hhs.gov/manuals/downloads/som107_pp_guidelines_ltcf.pdfShekelle, P., Maglione, M., Bagley, S., (2007) Comparative effectiveness of off-label use of atypical antipsychotics. Comparative Effectiveness Review No. 6, , Effectivehealthcare.ahrq.gov/repFiles/Atypical_Antipsychotics_Final_Report.pdf, (Prepared by the Southern California/RAND Evidence-based Practice Center under Contract 290-02-003.) Rockville, MD: Agency for Healthcare Research and QualityJanuarySultzer, D.L., Davis, S.M., Tariot, P.N., Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial (2008) Am J Psychiatry, 165, pp. 844-854. , CATIE-AD Study GroupCarson, S., McDonagh, M.S., Peterson, K., A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia (2006) J Am Geriatr Soc, 54, pp. 354-361Tran-Johnson, T.K., Sack, D.A., Marcus, R.N., Auby, P., McQuade, R.D., Oren, D.A., Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial (2007) J Clin Psychiatry, 68, pp. 111-119Grossberg, G.T., Desai, A.K., Management of Alzheimer's disease (2003) J Gerontol A Biol Sci Med Sci, 58, pp. 331-353Cummings, J.L., Benson, D.F., (1992) Dementia: A clinical approach, , 2nd ed. Boston, MA: Butterworth-HeinemannLyketsos, C.G., Colenda, C.C., Beck, C., Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease (2006) Am J Geriatr Psychiatry, 14, pp. 561-572. , Task Force of American Association for Geriatric PsychiatryBallard, C.G., Thomas, A., Fossey, J., A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome (2004) J Clin Psychiatry, 65, pp. 114-119de Deyn, P.P., Katz, I.R., Brodaty, H., Lyons, B., Greenspan, A., Burns, A., Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double blind trials in nursing home residents treated with risperidone (2005) Clin Neurol Neurosurg, 107, pp. 497-508Katz, I., de Deyn, P.P., Mintzer, J., Greenspan, A., Zhu, Y., Brodaty, H., The efficacy and safety of risperidone in the treatment of psychosis of Alzheimers disease and mixed dementia: A meta-analysis of 4 placebo controlled clinical trials (2007) Int J Geriatr Psychiatry, 22, pp. 475-484Schneider, L.S., Dagerman, K.S., Insel, P., Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials (2005) JAMA, 294, pp. 1934-1943Sink, K.M., Holden, K.F., Yaffe, K., Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence (2005) JAMA, 293, pp. 596-608Guidelines abstracted from the American Academy of Neurology's dementia guidelines for early detection, diagnosis and management of dementia (2003) J Am Geriatr Soc, 51, pp. 869-873. , AGS Clinical Practice CommitteeBallard, C., Lana, M.M., Theodoulou, M., A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) (2008) PLoS Med, 5, pp. e76. , Investigators DART ADSink, K.M., Holden, K.F., Yaffe, K., Pharmacologic treatment of neuropsychiatric symptoms of dementia: A review of the evidence (2005) JAMA, 293, pp. 596-608(2005) AAGP Atypical Position Statement, , http://www.aagponline.org/prof/antipsychstat_0705.asp, American Academy for Geriatric Psychiatry, Retrieved March 26, 2008, fromMadhusoodanan, S., Shah, P., Brenner, R., Gupta, S., Pharmacological treatment of the psychosis of Alzheimer's disease: What is the best approach? (2007) CNS Drugs, 21, pp. 101-115Trinh, N., Hoblyn, J., Mohanty, S., Yaffe, K., Efficacy of cholinesterase inhibitors in the treatment of neuro
